Moderna (NASDAQ:MRNA) has agreed to resolve a patent litigation in which Alnylam Pharmaceuticals (NASDAQ:ALNY) has alleged that the delivery technology used in the company’s COVID-19 vaccine has violated the latter’s patent rights.
According to court filings submitted on Thursday, the duo asked the U.S. District Court for the District of Delaware to dismiss two related cases containing Alnylam’s (ALNM) claims with prejudice, meaning that another case over the same claims cannot be refiled.
A spokesperson for Alnylam (ALNM) confirmed the resolution without disclosing further details, while Moderna (NASDAQ:MRNA) didn’t immediately respond to comments, Reuters reported.
Alnylam (ALNM), a company that develops RNA interference therapies, first took legal action against Moderna (NASDAQ:MRNA) and Pfizer (PFE) in 2022, claiming the two COVID-19 shot makers violated its patented technology related to delivering genetic material to the body.
ALNY asked a Delaware federal court to end its case against Pfizer (PFE) in May after receiving an unfavorable ruling from Judge Colm Connolly, who also ruled against the company in a separate case against Moderna in 2024. The U.S. Court of Appeals for the Federal Circuit upheld the latter ruling in June.